Repository logo
 
Publication

Influenza vaccine effectiveness in Europe: Results from the 2022–2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study

2024-01-10Journal article Open access
Simple item page
dc.contributor.authorMaurel, Marine
dc.contributor.authorPozo, Francisco
dc.contributor.authorPérez‐Gimeno, Gloria
dc.contributor.authorBuda, Silke
dc.contributor.authorSève, Noémie
dc.contributor.authorOroszi, Beatrix
dc.contributor.authorHooiveld, Mariette
dc.contributor.authorGómez, Verónica
dc.contributor.authorDomegan, Lisa
dc.contributor.authorMartínez‐Baz, Iván
dc.contributor.authorIlić, Maja
dc.contributor.authorCarnahan, Anna Sara
dc.contributor.authorMihai, Maria Elena
dc.contributor.authorMartínez, Ana
dc.contributor.authorGoerlitz, Luise
dc.contributor.authorEnouf, Vincent
dc.contributor.authorHorváth, Judit Krisztina
dc.contributor.authorDijkstra, Frederika
dc.contributor.authorRodrigues, Ana Paula
dc.contributor.authorBennett, Charlene
dc.contributor.authorTrobajo‐Sanmartín, Camino
dc.contributor.authorMlinarić, Ivan
dc.contributor.authorLatorre‐Margalef, Neus
dc.contributor.authorIvanciuc, Alina
dc.contributor.authorLopez, Aurora
dc.contributor.authorDürrwald, Ralf
dc.contributor.authorFalchi, Alessandra
dc.contributor.authorTúri, Gergő
dc.contributor.authorMeijer, Adam
dc.contributor.authorMelo, Aryse
dc.contributor.authorO'Donnell, Joan
dc.contributor.authorCastilla, Jesús
dc.contributor.authorVučina, Vesna Višekruna
dc.contributor.authorHagey, Tove Samuelsson
dc.contributor.authorLazar, Mihaela
dc.contributor.authorKaczmarek, Marlena
dc.contributor.authorBacci, Sabrina
dc.contributor.authorKissling, Esther
dc.contributor.authorVEBIS Study Team
dc.date.accessioned2025-03-06T13:42:28Z
dc.date.available2025-03-06T13:42:28Z
dc.date.issued2024-01-10
dc.descriptionThe VEBIS study team includes: Portugal - Verónica Gomez, Irina Kislaya, Ana Paula Rodrigues, Ausenda Machado (Departamento de Epidemiologia, Instituto Nacional de Saúde Dr Ricardo Jorge, Lisboa); Daniela Dias, Licínia Gomes, Raquel Guiomar, Camila Henriques, Miguel Lança, Aryse Melo, Nuno Verdasca (Departamento de Doenças Infeciosas, Instituto Nacional de Saúde Dr Ricardo Jorge, Lisboa).
dc.description.abstractBackground: Influenza A(H3N2) viruses dominated early in the 2022-2023 influenza season in Europe, followed by higher circulation of influenza A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated the influenza vaccine effectiveness (VE) using a multicentre test-negative study. Materials and methods: Primary care practitioners collected information and specimens from patients consulting with acute respiratory infection. We measured VE against any influenza, influenza (sub)type and clade, by age group, by influenza vaccine target group and by time since vaccination, using logistic regression. Results: We included 38 058 patients, of which 3786 were influenza A(H3N2), 1548 influenza A(H1N1)pdm09 and 3275 influenza B cases. Against influenza A(H3N2), VE was 36% (95% CI: 25-45) among all ages and ranged between 30% and 52% by age group and target group. VE against influenza A(H3N2) clade 2b was 38% (95% CI: 25-49). Overall, VE against influenza A(H1N1)pdm09 was 46% (95% CI: 35-56) and ranged between 29% and 59% by age group and target group. VE against influenza A(H1N1)pdm09 clade 5a.2a was 56% (95% CI: 46-65) and 79% (95% CI: 64-88) against clade 5a.2a.1. VE against influenza B was 76% (95% CI: 70-81); overall, 84%, 72% and 71% were among 0-14-year-olds, 15-64-year-olds and those in the influenza vaccination target group, respectively. VE against influenza B with a position 197 mutation of the hemagglutinin (HA) gene was 79% (95% CI: 73-85) and 90% (95% CI: 85-94) without this mutation. Conclusion: The 2022-2023 end-of-season results from the VEBIS network at primary care level showed high VE among children and against influenza B, with lower VE against influenza A(H1N1)pdm09 and A(H3N2).pt_PT
dc.description.sponsorshipThis study received funding from the European Centre for Disease Prevention and Control (ECDC) under the framework contract Vaccine Effectiveness, Burden and Impact Studies (VEBIS) of COVID-19 and Influenza ECDC/2021/019.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationInfluenza Other Respir Viruses . 2024 Jan 10;18(1):e13243. doi: 10.1111/irv.13243. eCollection 2024 Jan
dc.identifier.doi10.1111/irv.13243pt_PT
dc.identifier.issn1750-2640
dc.identifier.pmid38204584
dc.identifier.urihttp://hdl.handle.net/10400.18/10417
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherWiley
dc.relation.hasversionhttps://onlinelibrary.wiley.com/doi/10.1111/irv.13243
dc.relation.publisherversionhttps://onlinelibrary.wiley.com/doi/10.1111/irv.13243pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectInfluenzapt_PT
dc.subjectInfluenza Vaccine
dc.subjectVaccine Effectiveness
dc.subjectMulticentre Study
dc.subjectPrimary Carept_PT
dc.subjectVEBISpt_PT
dc.subjectEurope
dc.subjectInfecções Respiratórias
dc.subjectInvestigação em Serviços de Saúdept_PT
dc.subjectEstados de Saúde e de Doençapt_PT
dc.titleInfluenza vaccine effectiveness in Europe: Results from the 2022–2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre studypt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue1pt_PT
oaire.citation.startPagee13243
oaire.citation.titleInfluenza and Other Respiratory Viruses
oaire.citation.volume18pt_PT
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameGOMEZ TEIXEIRA PINTO
person.familyNameRodrigues
person.givenNameVERÓNICA DEL PILAR
person.givenNameAna Paula
person.identifier.ciencia-idFA1B-D68F-2611
person.identifier.orcid0000-0003-0485-0005
person.identifier.orcid0000-0003-2264-4723
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationeae04cda-2c73-437b-8666-6593d03aa34d
relation.isAuthorOfPublicationc23c6d96-e605-424f-abbb-64d783c73939
relation.isAuthorOfPublication.latestForDiscoveryc23c6d96-e605-424f-abbb-64d783c73939

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Influenza Resp Viruses - 2024 - Maurel - Influenza vaccine effectiveness in Europe Results from the 2022 2023 VEBIS .pdf
Size:
1.35 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

DEP - Artigos em revistas internacionais
DDI - Artigos em revistas internacionais
INSA - Artigos em revistas internacionais